Enteris BioPharma offers innovative formulation solutions built around its proprietary oral drug delivery technology platform – Peptelligence®. Since its founding in 2013, Enteris BioPharma has advanced into the clinic multiple internal and external programs leveraging its Peptelligence® platform. The technology has been developed and proven effective to enable the delivery of BSC III and IV compounds including peptides, peptidomimetics, and small molecules with low oral bioavailability. In addition to its formulation development expertise, Enteris BioPharma has a 32,000 square-foot GMP facility in Boonton, New Jersey, offering a range of manufacturing services. Enteris BioPharma operates as an independent, wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH). SWK offers Enteris with sound financial backing and long range planning support.

Enteris BioPharma white capsules for oral peptide drug delivery.

PEPTELLIGENCE^® & PROPERMA^™

Enteris BioPharma is the preferred partner in the oral drug delivery of BCS Class III and Class IV compounds, including peptides, peptidomimetics, and small molecules in an enteric-coated tablet.

LEARN MORE

Image of molecules in peptide drug delivery system developed by Enteris Biopharma.

PIPELINE

Enteris BioPharma internal pipeline of products are being clinically evaluated and include Ovarest^® for several treatments including orphan indications and Tobrate^™ for uUTIs.

LEARN MORE

CDMO SERVICE

Enteris BioPharma has a 32,000 square-foot GMP facility in Boonton, New Jersey offering an expanding range of manufacturing and development services.

LEARN MORE

EARLY DRUG DISCOVERY

LIFE CYCLE MANAGEMENT

PARTNERSHIPS

Enteris BioPharma builds long-term relationships, with proven novel formulation technology solutions and manufacturing services.

LEARN MORE

Enteris BioPharma Photo image of young child with binoculars looking into sunflower field at sunrise.

ABOUT US

Enteris BioPharma is an independent, wholly-owned subsidiary of SWK Holdings Corporation, a publically traded company (Nasdaq: SWKH) and offers innovative formulation solutions and manufacturing services. Enteris has access to capital and resources that it can direct towards expansion and growth opportunities.

LEARN MORE